6955 — Shandong Boan Biotechnology Co Income Statement
0.000.00%
Last trade - 00:00- HK$4.34bn
- HK$3.95bn
- CNY784.82m
Annual income statement for Shandong Boan Biotechnology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 159 | 516 | 618 | 726 | 785 |
| Cost of Revenue | |||||
| Gross Profit | 107 | 354 | 409 | 543 | 562 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 373 | 834 | 723 | 620 | 739 |
| Operating Profit | -214 | -318 | -105 | 106 | 45.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -225 | -332 | -119 | 73.2 | 7.14 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -225 | -332 | -119 | 73.2 | 7.14 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -225 | -332 | -119 | 73.2 | 7.14 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -225 | -332 | -119 | 73.2 | 7.14 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.438 | -0.579 | -0.234 | 0.137 | 0.012 |